• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study shows Alzheimer’s drug activates stem cells in teeth

January 10, 2017 By Sarah Faulkner

Study shows Alzheimer's drug activates stem cells in teethResearchers from King’s College London have shown that an Alzheimer’s drug can stimulate the stem cells found in tooth pulp and generate a protective material, dentine, in large cavities. The team’s work was published yesterday in Scientific Reports. 

If the soft pulp of a tooth becomes infected after a traumatic event, a thin layer of dentine is naturally produced to seal the pulp and protect the tooth from infection. But this layer is not enough to fix large cavities, so dentists use man-made fillings to fill holes in teeth.

The team from King’s College London used small molecules, including the Alzheimer’s drug Tideglusib, to trigger the body to make stem cells and create new dentine. Because the researchers used a drug which is already in practice, the treatment could potentially be fast-tracked.

“The simplicity of our approach makes it ideal as a clinical dental product for the natural treatment of large cavities, by providing both pulp protection and restoring dentine,” lead author Paul Sharpe said in prepared remarks. “In addition, using a drug that has already been tested in clinical trials for Alzheimer’s disease provides a real opportunity to get this dental treatment quickly into clinics.”

The researchers applied small doses of glycogen synthase kinase (GSK-3) inhibitors to the teeth of mice, using biodegradable collagen sponges to deliver the small molecule drugs. Over time, the sponge degraded and new dentine formed in its place.

Although the study was completed in mice, which have much smaller molars than humans, the team claimed that the anticipated concentrations of Tideglusib needed for human tooth repair would still be less than what has already been tested in clinical trials.

Filed Under: Featured, Neurological, Preclinical Trials, Research & Development, Stem Cells Tagged With: King's College London

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS